Systemic immune activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to activate naive CD4 T-cells

Nicole L Yonkers, Benigno Rodriguez, Robert Asaad, Michael M Lederman, Donald D Anthony, Nicole L Yonkers, Benigno Rodriguez, Robert Asaad, Michael M Lederman, Donald D Anthony

Abstract

Background: HIV infection is characterized by ineffective anti-viral T-cell responses and impaired dendritic cell (DC) functions, including response to Toll-Like Receptor (TLR) ligands. Because TLR responsiveness may affect a host's response to virus, we examined TLR ligand induced Myeloid and Plasmacytoid DC (MDC and PDC) activation of naïve T-cells in HIV+ subjects.

Methods: Freshly purified MDC and PDC obtained from HIV+ subjects and healthy controls were cultured in the presence and absence of TLR ligands (poly I∶C or R-848). We evaluated indices of maturation/activation (CD83, CD86, and HLA-DR expression), cytokine secretion (IFN-alpha and IL-6), and ability to activate allogeneic naïve CD4 T-cells to secrete IFN-gamma and IL-2.

Results: MDC from HIV+ subjects had increased spontaneous IL-6 production and increased CD83 and CD86 expression when compared to MDC of controls. MDC IL-6 expression was associated with plasma HIV level. At the same time, poly I∶C induced HLA-DR up-regulation on MDC was reduced in HIV+ persons when compared to controls. The latter finding was associated with impaired ability of MDC from HIV+ subjects to activate allogeneic naïve CD4 T-cells. PDC from HIV+ persons had increased spontaneous and TLR ligand induced IL-6 expression, and increased HLA-DR expression at baseline. The latter was associated with an intact ability of HIV PDC to activate allogeneic naïve CD4 T-cells.

Conclusion: These results have implications for the ability of the HIV+ host to form innate and adaptive responses to HIV and other pathogens.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. HIV subject DC exhibit increased…
Figure 1. HIV subject DC exhibit increased maturation.
Panel A. Representative flow cytometric analysis of freshly isolated MDC and PDC from one healthy control. Mean Fluorescent Intensity (MFI) for HLA-DR, CD86, and CD83 were analyzed. Panel B. Baseline activation/maturation phenotype of freshly isolated MDC and PDC from healthy control (n = 22) and HIV+ subjects (n = 24). The black line represents the median MFI value for each group for HLA-DR, CD86, and CD83.
Figure 2. DC TLR ligand responsiveness.
Figure 2. DC TLR ligand responsiveness.
Panels A and B. CD86 MFI and HLA-DR MFI on isolated MDC following overnight culture in presence of Medium and poly I∶C stimulation in healthy control (n = 21) and HIV+ subjects (n = 18). The p value in panel B is for comparison between the delta HLA-DR MFI for controls and HIV infected subjects . IL-6 production from isolated MDC on a subset of the same subjects (n = 18 control and n = 16 HIV+) (panel C) following overnight culture in absence and presence of poly I∶C stimulation. IL-6 production from isolated PDC on a subset of the same subjects (n = 17 control and n = 17 HIV+) (panel D) following overnight culture in absence and presence of R848 stimulation. Healthy control (n = 17) and HIV+ subject (n = 16) PDC IFN-α production in response to overnight R848 stimulation is shown in panel E. Panel . Association between MDC spontaneous IL-6 production and HIV plasma level.
Figure 3. HIV subject MDC are impaired…
Figure 3. HIV subject MDC are impaired in naïve CD4 T cell activation activity.
Freshly prepared MDC from healthy control (n = 17) and HIV+ (n = 18) subjects were used in titrated numbers (x-axis) to activate one healthy control subject's allogeneic naive CD4 T-cells to produce IFN-γ or IL-2 (y-axis) in a 72-h culture performed in the absence (Medium, panels A. and C.), or presence of poly I∶C (panels B. and D.). Control cultures of TLR ligand and naïve CD4 T cells resulted in <3 sfu IFN-γ, and data shown are sfu above this background.
Figure 4. HIV subject PDC are intact…
Figure 4. HIV subject PDC are intact for naïve CD4 T cell activation activity.
Freshly prepared PDC from healthy control (n = 13) and HIV+ (n = 10) subjects were used in titrated numbers (x-axis) to activate one healthy control subject's allogeneic naive CD4 T-cells to produce IFN-γ or IL-2 (y-axis) in a 72-h culture performed in the absence (Medium, panels A. and C.), or presence of R848 (panels B. and D.). Control cultures of TLR ligand and naïve CD4 T cells resulted in <3 sfu IFN-γ, and data shown are sfu above this background.
Figure 5. Increased PDL-1 and PDL-2 expression…
Figure 5. Increased PDL-1 and PDL-2 expression on HIV subject MDC.
Isolated MDC were evaluated for expression of inhibitory molecules PDL-1 (panel A) and PDL-2 (panel B) in control (n = 10) and HIV+ (n = 10) subjects. Black lines represent median MFI value for each group. Panel C. Association between PDL-1 MFI on MDC in HIV+ subjects and plasma HIV level. Panel D. The percentage of Annexin V+ T-cells are shown following naive T-cell co-cultures with control vs. HIV+ subject MDC (10,000cells/well) in the absence and presence of poly I∶C.

References

    1. Neilsen GA, Bodsworth NJ, Watts N. Response to Hepatitis A Vaccination in Human Immunodeficiency Virus-Infected and -Uninfected Homosexual Men. The Journal of Infectious Diseases. 1997;176:1064–1067.
    1. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. The American Journal of Medicine. 2005;118:75–83.
    1. Hay CM, Ruhl DJ, Basgoz NO, Wilson CC, Billingsley JM, et al. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol. 1999;73:5509–5519.
    1. Cohen DE, Walker BD. Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. Clin Infect Dis. 2001;32:1756–1768.
    1. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371.
    1. Meier A, Alter G, Frahm N, Sidhu H, Li B, et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol. 2007;81:8180–8191.
    1. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood. 2009;113:377–388.
    1. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999;283:1183–1186.
    1. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, et al. Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. J Immunol. 2002;168:4531–4537.
    1. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. European Journal of Immunology. 2001;31:3388–3393.
    1. Lore K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol. 2003;171:4320–4328.
    1. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987–995.
    1. Feldman S, Stein D, Amrute S, Denny T, Garcia Z, et al. Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol. 2001;101:201–210.
    1. Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol. 2002;168:4796–4801.
    1. Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood. 2001;98:906–912.
    1. Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, et al. Selective impairments in dendritic cell associated function distinguish HCV and HIV infection. J Immunol. 2004;172:4907–4916.
    1. Grassi F, Hosmalin A, McIlroy D, Calvez V, Debre P, et al. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS. 1999;13:759–766.
    1. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood. 2003;101:4505–4511.
    1. Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood. 2001;98:3016–3021.
    1. Dillon SM, Robertson KB, Pan SC, Mawhinney S, Meditz AL, et al. Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2008;48:1–12.
    1. Lehmann C, Lafferty M, Garzino-Demo A, Jung N, Hartmann P, et al. Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS One. 2010;5:e11110.
    1. Meera S, Madhuri T, Manisha G, Ramesh P. Irreversible loss of pDCs by apoptosis during early HIV infection may be a critical determinant of immune dysfunction. Viral Immunol. 2010;23:241–249.
    1. Lester RT, Yao XD, Ball TB, McKinnon LR, Kaul R, et al. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS. 2008;22:685–694.
    1. Sabado RL, O'Brien M, Subedi A, Qin L, Hu N, et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood. 2010:blood-2010-2003-273763.
    1. Martinson JA, Roman-Gonzalez A, Tenorio AR, Montoya CJ, Gichinga CN, et al. Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell Immunol. 2007;250:75–84.
    1. Nowroozalizadeh S, Mansson F, da Silva Z, Repits J, Dabo B, et al. Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine. 2009;46:325–331.
    1. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009;30:475–487.
    1. Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, et al. Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol. 2008;82:3997–4006.
    1. Anthony DD, Post AB, Valdez H, Peterson DL, Murphy M, et al. ELISPOT analysis of hepatitis C virus protein-specific IFN-gamma- producing peripheral blood lymphocytes in infected humans with and without cirrhosis. Clin Immunol. 2001;99:232–240.
    1. Karulin A, Hesse M, Tary-Lehmann M, Lehmann P. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J Immunol. 2000;164:1862–1872.
    1. Yonkers NL, Rodriguez B, Milkovich KA, Asaad R, Lederman MM, et al. TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol. 2007;178:4436–4444.
    1. Wang X, Zhang Z, Zhang S, Fu J, Yao J, et al. B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection. Eur J Immunol. 2008;38:3226–3236.
    1. Cai G, Karni A, Oliveira EML, Weiner HL, Hafler DA, et al. PD-1 ligands, negative regulators for activation of naïve, memory, and recently activated human CD4+ T cells. Cellular Immunology. 2004;230:89–98.
    1. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350–354.
    1. Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood. 2003;101:2514–2520.
    1. Meier A, Bagchi A, Sidhu HK, Alter G, Suscovich TJ, et al. Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS. 2008;22:655–658.
    1. Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, et al. Striking Dichotomy of PD-L1 and PD-L2 Pathways in Regulating Alloreactive CD4+ and CD8+ T Cells In Vivo. American Journal of Transplantation. 2007;7:2683–2692.
    1. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548.
    1. Vlad G, Chang C-C, Colovai AI, Berloco P, Cortesini R, et al. Immunoglobulin-like transcript 3: A crucial regulator of dendritic cell function. Human Immunology. 2009;70:340–344.
    1. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–9553.
    1. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol. 1991;147:1567–1574.
    1. Lien E, Aukrust P, Sundan A, Muller F, Froland SS, et al. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood. 1998;92:2084–2092.
    1. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol. 2002;80:477–483.
    1. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.
    1. Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol. 2001;13:291–298.
    1. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol. 2002;168:197–206.
    1. Granelli-Piperno A, Shimeliovich I, Pack M, Trumpfheller C, Steinman RM. HIV-1 selectively infects a subset of nonmaturing BDCA1-positive dendritic cells in human blood. J Immunol. 2006;176:991–998.
    1. Cai G, Karni A, Oliveira EM, Weiner HL, Hafler DA, et al. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol. 2004;230:89–98.
    1. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.
    1. Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13:177–187.

Source: PubMed

3
Tilaa